Analytes of interest and choice of dose: Two important considerations in the design of bioequivalence studies with atorvastatin

Journal of Bioequivalence and Bioavailability

Volumn 3, Issue 4, 2011, Pages 62-68

  Gandelman, Kuan ^a   Malhotra, Bimal ^a   Labadie, Robert R ^b   Crownover, Penelope ^a   Bergstrom, Tamie ^a  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Atorvastatin; Bioequivalence; Chewable tablet; Marketed tablet; Small tablet

Indexed keywords

ATORVASTATIN; DRUG METABOLITE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; STUDY DESIGN; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 79958696913     PISSN: None     EISSN: 09750851     Source Type: Journal    
DOI: 10.4172/jbb.1000060     Document Type: Article

References (26)

1. Cánovas M, Delgadillo J, Torres F, Riba N, Cebrecos J, et al. (2009) Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers. Int J Clin Pharmacol Ther 47:124-131.
2. Chung M, Calcagni A, Glue P, Bramson C (2006) Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol 46:1212-1216.
3. Cilla DD Jr., Whitfield LR, Gibson DM, Sedman AJ, Posvar EL (1996) Multipledose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of H MG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 60:687-695.
4. Davidson MH, Robinson JG (2007) Safety of aggressive lipid management. J Am Coll Cardiol 49:1753-1762.
5. European Medicines Agency (2006) Questions & answers on the note for guidance on the investigation of bioavailability and bioequivalence. EMEA/CHMP/EWP/40326/2006.
6. European Medicines Agency (2008) Guideline on the investigation of bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1).
7. European Medicines Agency (2010) Guideline on the investigation of bioequivalence (CHMP/EWP/QWP/1401/98 Rev. 1).
8. García MJ, Reinoso RF, Sánchez Navarro A, Prous JR (2003) Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 25:457-481.
9. Health Canada TPD (1992) Guidance for industry on conduct and analysis of bioavailability and bioequivalence studies Part A: Oral dosage formulations used for systemic effects.
10. Health Canada TPD (2003) Guidance for industry on bioequivalence requirements: drugs exhibiting non-linear pharmacokinetics.
11. Health Canada TPD (2010) Conduct and analysis of comparative bioavailability studies and comparative bioavailability standards: Formulations used for systemic effects.
12. Lee SL, Raw AS, Yu L (2008) Dissolution Testing. In:Krishna R, Yu L (eds) Biopharmaceutics Applications in Drug Development. Springer US Publisher, pp.47-74.
13. Lennernas H (2003) Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141-1160.
14. Mehvar R (2001) Principles of nonlinear pharmacokinetics. American Journal of Pharmaceutical Education 65:178-184.
15. Pfizer Inc. Lipitor (2009) (atorvastatin calcium) full prescribing information.
16. Posvar EL, Radulovic LL, Cilla DD, Whitfield LR, Sedman AJ (1996) Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMGCoA reductase, in healthy subjects. J Clin Pharmacol 36:728-731.
17. Rowland M, Tozer TN (1995) Extravascular dose. In: Clinical Pharmacokinetics: Concepts and Applications, 3rd edition, Lippincott Williams & Wilkins, Philadelphia, USA, pp.34-46.
18. US FDA (2000) Guidance on waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. August 2000.
19. US FDA (2003) Guidance on bioavailability and bioequivalence studies for orally administered drug products - general considerations.
20. US FDA (2008) Office of generic drugs guidance on atorvastatin calcium.
21. US FDA (2008) Office of generic drugs guidance on simvastatin.
22. US FDA (2009) Office of generic drugs guidance on pioglitazone hydrochloride.
23. Wu C-Y, Benet LZ (2005) Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22: 11-23.
24. Wong H, Ozalp Y, Lainesse A, Alpan RS (2004). In-vivo bioequivalence of oral anti-diabetic agents: pioglitazone tablets. Arzneimittelforschung 54: 618-624.
25. Yang BB, Smithers JA, Stern RH, Sedman AJ, Olson SC (1996) Pharmacokinetics and dose proportionality of atorvastatin and its active metabolites. Pharm Res 9 (Suppl):S437.
26. Newman C, Tsai J, Szarek M, Luo D, Gibson E (2006) Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 97:61-67.